Skip to main content
Top
Published in: Calcified Tissue International 5/2021

01-05-2021 | Hypophosphatemic Rickets | Original Research

Does Genotype–Phenotype Correlation Exist in Vitamin D-Dependent Rickets Type IA: Report of 13 New Cases and Review of the Literature

Authors: Sare Betul Kaygusuz, Ceren Alavanda, Tarik Kirkgoz, Mehmet Eltan, Zehra Yavas Abali, Didem Helvacioglu, Tulay Guran, Pinar Ata, Abdullah Bereket, Serap Turan

Published in: Calcified Tissue International | Issue 5/2021

Login to get access

Abstract

Vitamin D-dependent rickets type IA (VDDR-IA) is caused by biallelic mutations in CYP27B1. Data regarding genotype–phenotype correlation in VDDR-IA are scarce. Here, we aimed to investigate clinical/genotypic features and long-term follow-up of 13 new cases with VDDR-IA and genotype–phenotype correlation of reported cases in the literature. Thirteen patients with VDDR-IA were evaluated. Eight patients had reached their final height at the time of the study and, for whom, long-term outcome data were analyzed. Further, all VDDR-IA patients in the literature (n:183) were analyzed and clinical–genetic features were recorded. The median age of diagnosis was 2.55 ± 1.13 (1.0–12) years. Initial diagnoses before referral to our clinic were nutritional rickets (n:7), hypophosphatemic rickets (n:2), and pseudohypoparathyroidism (n:1). All had biochemical evidence suggestive of VDDR-IA; except one with elevated 1,25(OH)2D3 and another with hyperphosphatemia, in whom pseudohypoparathyroidism was excluded with molecular tests. Combined analyses of our cohort and other series in the literature demonstrated that three most common CYP27B1 mutations are p.F443Pfs*24, c.195 + 2T > G, and p.V88Wfs*71. In Turkish population, p.K192E mutation along with the former two is the most common mutations. Comparison of clinical features demonstrated that c.195 + 2T > G mutation causes the most severe and p.K192E mutation causes the least severe phenotype with respect to age and height at presentation and calcitriol requirement. We found a clear genotype–phenotype correlation in VDDR-IA, notably CYP27B1 intronic c.195 + 2T > G mutation causes a more severe phenotype with lower height SDS at presentation and, higher calcitriol requirement, while less severe phenotype occurs in p.K192E mutation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chiellini G, DeLuca F (2011) The importance of stereochemistry on the actions of vitamin D. Curr Top Med Chem 11:840–859CrossRef Chiellini G, DeLuca F (2011) The importance of stereochemistry on the actions of vitamin D. Curr Top Med Chem 11:840–859CrossRef
3.
go back to reference Roizen JD, Li D, O’Lear L et al (2018) CYP3A4 mutation causes vitamin D-dependent rickets type 3. J Clin Invest 128:1913–1918CrossRef Roizen JD, Li D, O’Lear L et al (2018) CYP3A4 mutation causes vitamin D-dependent rickets type 3. J Clin Invest 128:1913–1918CrossRef
4.
go back to reference Fraser D, Kooh SW, Kind HP et al (1973) Pathogenesis of hereditary vitamin-D-dependent rickets: an inborn error of vitamin D metabolism involving defective conversion of 25-hydroxyvitamin D to 1α, 25-dihydroxyvitamin D. N Engl J Med 289:817–822CrossRef Fraser D, Kooh SW, Kind HP et al (1973) Pathogenesis of hereditary vitamin-D-dependent rickets: an inborn error of vitamin D metabolism involving defective conversion of 25-hydroxyvitamin D to 1α, 25-dihydroxyvitamin D. N Engl J Med 289:817–822CrossRef
10.
go back to reference Untergasser A, Cutcutache I, Koressaar T et al (2012) Primer3—new capabilities and interfaces. Nucleic Acids Res 40:e115–e115CrossRef Untergasser A, Cutcutache I, Koressaar T et al (2012) Primer3—new capabilities and interfaces. Nucleic Acids Res 40:e115–e115CrossRef
11.
go back to reference Stenson PD, Ball EV, Mort M et al (2003) Human gene mutation database (HGMD®): 2003 update. Hum Mutat 21:577–581CrossRef Stenson PD, Ball EV, Mort M et al (2003) Human gene mutation database (HGMD®): 2003 update. Hum Mutat 21:577–581CrossRef
19.
go back to reference Smith SJ, Rucka AK, Berry JL et al (1999) Three families with pseudovitamin D-deficiency rickets resulting in loss of functional enzyme activity. J bone Miner Res 14:730–739CrossRef Smith SJ, Rucka AK, Berry JL et al (1999) Three families with pseudovitamin D-deficiency rickets resulting in loss of functional enzyme activity. J bone Miner Res 14:730–739CrossRef
21.
go back to reference Beck-Nielsen SS, Hertel NT, Brock-Jacobsen B (2006) Vitamin D 1 alpha-hydroxylase deficiency as the cause of severe rickets in a 1-year-old-old boy. Ugeskr Laeger 168:700–702PubMed Beck-Nielsen SS, Hertel NT, Brock-Jacobsen B (2006) Vitamin D 1 alpha-hydroxylase deficiency as the cause of severe rickets in a 1-year-old-old boy. Ugeskr Laeger 168:700–702PubMed
22.
go back to reference Porcu L, Meloni A, Casula L et al (2002) A novel splicing defect (IVS6+ 1G> T) in a patient with pseudovitamin D deficiency rickets. J Endocrinol Invest 25:557–560CrossRef Porcu L, Meloni A, Casula L et al (2002) A novel splicing defect (IVS6+ 1G> T) in a patient with pseudovitamin D deficiency rickets. J Endocrinol Invest 25:557–560CrossRef
23.
go back to reference Orbak Z (2017) A novel mutation of CYP27B1 in two siblings with vitamin D-dependent rickets type 1A. In: 8th International Conference on Children Orbak Z (2017) A novel mutation of CYP27B1 in two siblings with vitamin D-dependent rickets type 1A. In: 8th International Conference on Children
24.
go back to reference Kitanaka S, Murayama A, MToshioyuki S et al (1999) No enzyme activity of 25-hydroxyvitamin D3 1-a hydroxylase gene product in pseudovitamin D deficiency rickets, including that with mild clinical manifestation. J Clin Endocrinol Metab 84:4111–4117PubMed Kitanaka S, Murayama A, MToshioyuki S et al (1999) No enzyme activity of 25-hydroxyvitamin D3 1-a hydroxylase gene product in pseudovitamin D deficiency rickets, including that with mild clinical manifestation. J Clin Endocrinol Metab 84:4111–4117PubMed
26.
go back to reference Alzahrani AS, Zou M, Baitei EY et al (2010) Alzahrani2010 a novel G102E mutation of CYP27B1 in a large family with vitamin D-dependent rickets type 1.pdf. J Clin Endocrinol Metab 95:4176–4183CrossRef Alzahrani AS, Zou M, Baitei EY et al (2010) Alzahrani2010 a novel G102E mutation of CYP27B1 in a large family with vitamin D-dependent rickets type 1.pdf. J Clin Endocrinol Metab 95:4176–4183CrossRef
31.
go back to reference Kitanaka S, Takeyama K, Murayama A et al (1998) Inactivating mutations in the 25-hydroxyvitamin D3 1α-hydroxylase gene in patients with pseudovitamin D-deficiency rickets. N Engl J Med 338:653–662CrossRef Kitanaka S, Takeyama K, Murayama A et al (1998) Inactivating mutations in the 25-hydroxyvitamin D3 1α-hydroxylase gene in patients with pseudovitamin D-deficiency rickets. N Engl J Med 338:653–662CrossRef
32.
34.
go back to reference Nishikawa M, Yasuda K, Takamatsu M et al (2019) Generation of 1, 25-dihydroxyvitamin D3 in Cyp27b1 knockout mice by treatment with 25-hydroxyvitamin D3 rescued their rachitic phenotypes. J Steroid Biochem Mol Biol 185:71–79CrossRef Nishikawa M, Yasuda K, Takamatsu M et al (2019) Generation of 1, 25-dihydroxyvitamin D3 in Cyp27b1 knockout mice by treatment with 25-hydroxyvitamin D3 rescued their rachitic phenotypes. J Steroid Biochem Mol Biol 185:71–79CrossRef
36.
go back to reference Wang J, Slominski A, Tuckey RC, Janjetovic Z (2012) 20-Hydroxyvitamin D3 inhibits proliferation of cancer cells with high efficacy while being non-toxic. Anticancer Res 32:739–746PubMedPubMedCentral Wang J, Slominski A, Tuckey RC, Janjetovic Z (2012) 20-Hydroxyvitamin D3 inhibits proliferation of cancer cells with high efficacy while being non-toxic. Anticancer Res 32:739–746PubMedPubMedCentral
Metadata
Title
Does Genotype–Phenotype Correlation Exist in Vitamin D-Dependent Rickets Type IA: Report of 13 New Cases and Review of the Literature
Authors
Sare Betul Kaygusuz
Ceren Alavanda
Tarik Kirkgoz
Mehmet Eltan
Zehra Yavas Abali
Didem Helvacioglu
Tulay Guran
Pinar Ata
Abdullah Bereket
Serap Turan
Publication date
01-05-2021
Publisher
Springer US
Published in
Calcified Tissue International / Issue 5/2021
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-020-00784-2

Other articles of this Issue 5/2021

Calcified Tissue International 5/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine